Search results
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 hour agoNektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript May 9, 2024 Nektar Therapeutics...
BofA bullish on Apogee stock, sees significant market growth potential By Investing.com
Investing.com· 8 hours agoFriday, BofA Securities initiated coverage on Apogee (NASDAQ:APOG) Therapeutics Inc (NASDAQ:APGE)...
...Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual...
Benzinga· 3 days agoThe KOL event, "Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of ...
New treatment could reverse hair loss caused by autoimmune skin disease alopecia areata
Medical Xpress· 1 day agoThe team has developed a microneedle patch that can be painlessly applied to the scalp and releases...
Jefferies raises Nektar Therapeutics stock target, maintains hold By Investing.com
Investing.com· 5 hours agoThe company is currently enrolling patients for a Phase 2b study of rezpeg in Atopic Dermatitis...
Warner Bros. upgraded, Cerence downgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 8 hours agoBofA initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $80 price target. The...
Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
GuruFocus.com via Yahoo Finance· 3 days agoThere are inherent risks in drug development, highlighted by the need for reevaluation of ATI 2138's indication selection, which can lead to delays and increased costs. The competitive landscape ...
A tailored vaccine shows promise in treating childhood eczema
MedicalNewsToday via AOL· 3 days agoThey say the vaccines would be tailored to children’s individual “immune signatures.” Current ...
Managing Comorbidities in Chronic Urticaria
MedPage Today· 2 days agoThe link between chronic urticaria and atopic diseases, autoimmune diseases, and psychiatric disorders has significant implications for clinical practice. Managing comorbidities ...
Nektar Therapeutics Reports First Quarter 2024 Financial Results
The West Side Index & Gustine Press-Standard· 1 day agoNektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securities at March 31, 2024 were $326.0 million ...
